Oblimersen and Doxorubicin in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)

Liver Cancer Clinical Trial

Official title:

A Phase II Study of G3139 in Combination With Doxorubicin in Advanced Hepatocellular Carcinoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00047229
• Other study ID #: PMH-PHL-011
• Secondary ID: CDR0000257565NCI
• Status: Completed
• Phase: Phase 2
• First received: October 3, 2002
• Last updated: November 6, 2017
• Start date: October 2002
• Est. completion date: April 2009

Study information

• Verified date: November 2017
• Source: University Health Network, Toronto
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy such as doxorubicin use different ways to stop tumor cells from dividing so they stop growing or die. Oblimersen may increase the effectiveness of doxorubicin by making tumor cells more sensitive to the drug.

PURPOSE: Phase II trial to study the effectiveness of combining oblimersen with doxorubicin in treating patients who have locally advanced, recurrent, or metastatic hepatocellular carcinoma (liver cancer).

Description:

OBJECTIVES:

• Determine the maximum tolerated dose of oblimersen and doxorubicin in patients with advanced hepatocellular carcinoma or other incurable solid tumor (closed to accrual as of 11/7/03). (Phase I completed as of 1/16/04.)

• Determine the efficacy of this regimen, in terms of objective response rate, in these patients.

• Determine the toxicity of this regimen in these patients.

• Determine the time to progression, response duration, progression-free survival, median survival, and overall survival rates in patients treated with this regimen.

OUTLINE: This is a dose-escalation, multicenter study. (Phase I completed as of 1/16/04.)

Patients receive oblimersen IV continuously on days 1-7 and doxorubicin IV over 5 minutes on day 5. Treatment repeats every 4 weeks for up to 10 courses in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of oblimersen and doxorubicin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, additional patients*, including 6 patients with hepatocellular carcinoma (HCC), are treated at the recommended phase II dose. (Phase I completed as of 1/16/04.)

NOTE: *Other solid tumors closed to accrual as of 11/7/03; only accruing HCC patients

PROJECTED ACCRUAL: A total of 12-18 patients will be accrued for the phase I portion of this study within 6 months (phase I completed as of 1/16/04). A total of 30 patients will be accrued for the phase II portion of this study within 10-15 months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 27
• Est. completion date: April 2009
• Est. primary completion date: January 2009
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 120 Years

Eligibility

DISEASE CHARACTERISTICS:

• Diagnosis of 1 of the following:

• Histologically or cytologically confirmed hepatocellular carcinoma (HCC)

• Locally advanced, recurrent, or metastatic

• Not candidates for surgical/radical therapies

• Other solid tumor that is incurable (closed to accrual as of 11/7/03)

• At least 1 unidimensionally measurable lesion

• At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan

• Target lesion may not be in a previously irradiated field unless subsequent progression was documented

• No ascites

• No known brain metastases

PATIENT CHARACTERISTICS:

Age

• 18 and over

Performance status

• ECOG 0-2 OR

• Karnofsky 60-100%

Life expectancy

• More than 3 months

Hematopoietic

• WBC at least 2,000/mm^3

• Absolute neutrophil count at least 1,500/mm^3

• Platelet count at least 100,000/mm^3

Hepatic

• Bilirubin no greater than 2.0 mg/dL

• AST no greater than 5 times upper limit of normal (ULN)

• Albumin greater than 3.5 g/dL

• No cirrhosis worse than Childs-Pugh class A

Renal

• Creatinine no greater than 1.25 times ULN OR

• Creatinine clearance at least 50 mL/min

Cardiovascular

• LVEF normal by MUGA

• No symptomatic congestive heart failure

• No unstable angina pectoris

• No cardiac arrhythmia

Other

• Good nutritional status

• No encephalopathy

• No other concurrent uncontrolled illness

• No ongoing or active infection

• No psychiatric illness or social situation that would preclude study participation

• No prior allergic reactions to compounds of similar chemical or biological composition to oblimersen or doxorubicin

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy

• No more than 1 prior biologic therapy regimen for patients with HCC

• At least 4 weeks since prior biologic therapy

Chemotherapy

• Patients with HCC:

• No prior systemic chemotherapy

• Prior chemotherapy as part of localized chemoembolization therapy may be allowed (no more than 150 mg/m^2 for doxorubicin) if completed at least 8 weeks before study treatment

• All other patients (closed to accrual as of 11/7/03):

• At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)

• No prior doxorubicin, epirubicin, or other anthracycline

Endocrine therapy

• Not specified

Radiotherapy

• See Disease Characteristics

• At least 4 weeks since prior radiotherapy

• No more than 3,000 cGy to fields including substantial bone marrow

Surgery

• At least 8 weeks since prior surgery

• Prior liver transplant for HCC allowed

Other

• Recovered from all prior therapy

• At least 8 weeks since other locally ablative therapies

• No concurrent commercial or other investigational agents or therapies

• No other concurrent anticancer therapy

• No concurrent combination antiretroviral therapy for HIV-positive patients

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular
• Liver Cancer
• Liver Neoplasms

Intervention

Biological:
• oblimersen sodium

Drug:
• doxorubicin hydrochloride

Locations

Country	Name	City	State
Canada	London Regional Cancer Program at London Health Sciences Centre	London	Ontario
Canada	Princess Margaret Hospital	Toronto	Ontario
Canada	British Columbia Cancer Agency - Vancouver Cancer Centre	Vancouver	British Columbia

Sponsors (2)

Lead Sponsor	Collaborator
University Health Network, Toronto	National Cancer Institute (NCI)

Country where clinical trial is conducted

Canada, 

References & Publications (2)

Knox JJ, Chen E, Feld R, et al.: A phase II trial of oblimersen sodium (G3139) in combination with doxorubicin (DOX) in advanced hepatocellular carcinoma (HCC). NCI protocol # 5798. [Abstract] J Clin Oncol 24 (Suppl 18): A-14072, 2006.

Knox JJ, Chen XE, Feld R, Nematollahi M, Cheiken R, Pond G, Zwiebel JA, Gill S, Moore M. A phase I-II study of oblimersen sodium (G3139, Genasense) in combination with doxorubicin in advanced hepatocellular carcinoma (NCI # 5798). Invest New Drugs. 2008 A — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of objective response (complete and partial)	Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Objective Response (OR) = CR + PR. Objective response rate of >= 30% is considered active, and <10% is considered inactive.	Up to 280 days
Secondary	Stable disease rate		Up to 280 days
Secondary	Duration of response		Up to 280 days
Secondary	Progression-free survival rate		Up to 280 days
Secondary	Median survival rate		Up to 280 days
Secondary	Overall survival rate		Up to 280 days
Secondary	Safety and tolerability		Up to 280 days

External Links

•   Clinical trial summary from the National Cancer Institute's PDQ® database